Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$2.02 +0.50%

+$0.01 today

Market cap
$191.34M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.20M

Average 0.48M

CGEN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Compugen Ltd.NASDAQ: CGEN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 16.2%

Gross margin was 16.2% in Q1 FY2026, up 21.3 pp from a year earlier. On a trailing-twelve-month basis it was 88.1%, up 17.9 pp year over year. Over 3 fiscal years it widened by 0.3 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
16.2%-78.6 pp QoQ
Last fiscal yearDec 2025
87.3%+15.7 pp YoY
LTMMar 2026
88.1%+17.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+21.3 pp——
1 year+15.7 pp——
3 years+0.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
87.3%
Year-over-year change
+15.7pp

Gross Margin vs competitors

How CGEN compares with its peers on the latest reported figures

  • CGEN's LTM Mar 2026 gross margin of 88.1% is the 4th highest of the 6 companies compared; the peer median is 94.7%.
  • Its year-over-year change of +17.9 pp is the 2nd highest of 5, against a peer median of -2.5 pp.
  • Over three fiscal years its change of +0.3 pp compares with a peer median of +0.0 pp.
CGEN Competitors Peer median
Gross Margin for CGEN and competitors
Company Period LTM level YoY 3-year change
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
RANIRani Therapeutics Holdings, Inc.LTM Mar 202694.9% -5.1 pp—
MISTMilestone Pharmaceuticals Inc.LTM Mar 202694.7% —-7.4 pp
CGENCompugen Ltd.LTM Mar 202688.1% +17.9 pp+0.3 pp
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 202652.6% +22.8 pp—
CRDFCardiff Oncology, Inc.LTM Mar 2026-2105.7% -548.4 pp+0.0 pp
NVCTNuvectis Pharma, Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
Peer median (excluding CGEN) 94.7%-2.5 pp+0.0 pp

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6M7.5M33.46M27.86M72.76M
Cost of Revenue680K975K2M7.93M9.25M
Gross Profit5.32M6.53M31.46M19.93M63.51M
Gross Margin88.7%87.0%94.0%71.5%87.3%
Research & Development28.69M30.65M34.47M24.81M22.76M
Selling, General & Admin11.7M11.25M9.98M10.02M9.43M
Operating Expenses40.39M41.9M44.45M34.83M32.19M
Depreciation & Amortization461K482K476K486K475K
EBITDA(33.72M)(33.13M)(9.28M)(9.19M)35.87M
EBITDA Margin-562.0%-441.7%-27.7%-33.0%49.3%
Operating Income(35.07M)(35.37M)(12.99M)(14.89M)31.33M
Operating Margin-584.6%-471.7%-38.8%-53.4%43.1%
Interest Income894K1.44M3.24M5.24M4.41M
Interest Expense25K27K31K34K0
Other Income / Expenses871K1.74M3.21M5.18M4.07M
Income Before Tax(34.2M)(33.64M)(9.78M)(9.71M)35.4M
Pre-Tax Margin-570.0%-448.5%-29.2%-34.8%48.6%
Income Tax Expense058K8.97M4.52M54K
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Net Margin-570.0%-449.3%-56.1%-51.1%48.6%
EPS (Basic)(0.41)(0.39)(0.21)(0.16)0.38
EPS (Diluted)(0.41)(0.39)(0.21)(0.16)0.38
Weighted Avg Shares84.2M86.56M87.63M89.53M93.43M
Weighted Avg Shares (Diluted)84.2M86.56M87.63M89.53M93.82M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$2.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.